Core Laboratories N.V. (CLB) announced its most recent quarterly financial results on Wednesday, Oct-19-2016. CLB reported $0.38 EPS for the quarter. Analysts had a consensus estimate of $0.38. The company posted revenue of $143.50 million in the period, compared to analysts expectations of $145.16 million. CLB’s revenue was down -27.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.83 EPS.
Many Wall Street Analysts have commented on Core Laboratories N.V.. Credit Suisse Initiated Core Laboratories N.V. on Sep 1, 2016 to “Neutral”, Price Target of the shares are set at $115.
Core Laboratories N.V. closed down -1.24 points or -1.10% at $111.41 with 3,11,242 shares getting traded on Friday. Post opening the session at $113.11, the shares hit an intraday low of $110.52 and an intraday high of $113.58 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Feb 3, 2016, Jan Willem Sodderland (director) purchased 300 shares at $93.90 per share price. According to the SEC, on May 13, 2015, Michael C Kearney (director) sold 1,000 shares at $128.52 per share price. On Feb 3, 2015, Kempen Margaret Ann Van (director) purchased 250 shares at $102.07 per share price, according to the Form-4 filing with the securities and exchange commission.
Core Laboratories N.V. (Core Lab) is a provider of proprietary and patented reservoir description production enhancement and reservoir management services to the oil and gas industry. These services and products are directed toward enabling its clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company operates in three segments: Reservoir Description Production Enhancement and Reservoir Management. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.